HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

SNG001 Fails Primary Endpoints, But May Alleviate Long COVID Symptoms

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Post-acute sequelae of COVID-19, also known as post-COVID-19 conditions or “long COVID,” can affect as many as 1 in 5 people who contract SARS-CoV-2. The debilitating symptoms of long COVID can last for months.

Interferon beta (IFN-β) is essential for the immune system to defend against COVID-19 and other viruses, but adept pathogens can suppress this defense mechanism. The SPRINTER trial (NCT04732949) evaluated the efficacy of inhalable SNG001, an IFN-β-1a nebulizer solution, in restoring lung IFN-β levels.

Data from Synairgen’s randomized controlled trial were presented at the IDWeek 2022 conference on Friday, 10/21, at a late-breaking session. While SNG001 did not meet the primary endpoints of time to discharge or recovery due to improvements in standard-of-care, there were promising secondary endpoints met.

The SPRINTER trial analyzed inhaled IFN-β in hospitalized COVID-19 patients. Patients who required low-flow oxygen were randomized to receive either SNG001 (n = 314) or placebo (n = 309) once a day for 14 days, in addition to receiving standard-of-care.

As a secondary endpoint, the investigators assessed long COVID symptoms at follow-up phone or video calls on days 60 and 90. They also examined patient reported outcomes, recorded via General Anxiety Disorder 7 Questionnaire (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale and Brief Pain Inventory (Short Form).

Compared to placebo, SNG001 reduced the relative risk of common long COVID symptoms, including a 35.4% reduction in fatigue/malaise, 28.3% reduction of dyspnea, and 61.4% reduction in loss of taste/smell.

The study authors noted that despite the failure to reduce time to discharge or recovery, SNG001 has potential to treat post-acute sequelae of COVID-19. They concluded that “the shift from pandemic to endemic status for COVID-19” supports the continued investigation of SNG001 for common long COVID symptoms.

This late-breaking study, “Impact of Treatment of Hospitalized COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial,” was presented by Phillip D. Monk, PhD, at IDWeek 2022, held October 19-23, 2022, in Washington, D.C.